Eli Lilly's COVID antibody combo given FDA emergency approval

Wednesday, 10. February 2021 03:45

The United States Food and Drug Administration (FDA) announced it has given emergency use authorization for Eli Lilly and Co.'s combination antibody therapy for use in people with mild-to-moderate COVID-19 symptoms.

"Today's action, which provides another treatment for COVID-19, reflects the FDA’s strong commitment to working with sponsors to expand potential treatment options health care providers can use to fight this pandemic," said Patrizia Cavazzoni, acting director of the agency's Center for Drug Evaluation and Research.

The treatment in question combines the previously authorized bamlanivimab with etesevimab and cannot be used on hospitalized individuals or those that require oxygen therapy. Following the approval, the federal government is set to distribute the treatment to state health departments.

Related Links: Eli Lilly & Company
Baha Breaking News (BBN) / NL